TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy

Primary and adaptive resistance to immune checkpoint therapies (ICT) represent a considerable obstacle to achieving enhanced overall survival. Innate immune activators have been actively pursued for their antitumor potential. Herein we report that a syngeneic 4T1 mammary carcinoma murine model for e...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez, Caleb, Williamson, Sarah, Gammon, Seth T., Glazer, Sarah, Rhee, Joon Haeng, Piwnica-Worms, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837180/
https://www.ncbi.nlm.nih.gov/pubmed/36635337
http://dx.doi.org/10.1038/s42003-022-04403-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837180/
https://www.ncbi.nlm.nih.gov/pubmed/36635337
http://dx.doi.org/10.1038/s42003-022-04403-8

Ejemplares similares